Introduction {#Sec1}
============

The epidemiology of obesity was prevalent and increasing dramatically worldwide in the past three decades^[@CR1]^. Recently, the trend of obesity was reported to be accelerating in some developed countries^[@CR2]^. It had become a growing public health issue not only in kinds of comorbidities but also in quality of life in Taiwan^[@CR3]^. Obesity was proposed to be related to several adverse health outcomes such as metabolic syndrome (MetS), diabetes mellitus (DM), hypertension (HTN) and increased morbidity and mortality^[@CR4]^. Numerous studies had proposed the associations between different obesity indices with metabolic disorders. As a traditional and commonly used indicator, body mass index (BMI) was reported to be associated with MetS and the risks of DM^[@CR5]^. Abdominal obesity, caused by visceral fat accumulation, was significantly associated with insulin resistance^[@CR6]^. Waist circumference (WC) was considered as a better index to predict MetS than others^[@CR7]^.

Body fat distribution was reported to have a significant association with the development of impaired glucose metabolism and MetS^[@CR8],[@CR9]^. In a previous study, high percentage body fat (PBF) was associated with a high cardiometabolic risks in Korean population^[@CR10]^. Besides, PBF had association with all-cause and cardiovascular mortality, high fat mass had higher mortality risk than BMI^[@CR11],[@CR12]^. Therefore, it may be crucial to determine the clinical usefulness of measuring PBF to evaluate the obesity-associated metabolic dysfunction. The aim of our study was to detemine whether the different obesity phenotypes were closely related to glucose intolerance and HTN.

Results {#Sec2}
=======

Demographic characteristics of the study sample {#Sec3}
-----------------------------------------------

All demographic information of study participants was shown in Table [1](#Tab1){ref-type="table"}. The mean age of these obesity phenotypes was 43.7 ± 14.5, 44.9 ± 13.4, 48.7 ± 12.3, and 50.6 ± 13.4 years, respectively. All participants were divided into four obesity phenotypes: BMI \> 27 kg/m^2^ (O), high waist circumference (male \> 90 cm, female \> 80 cm) (W), fatty liver (F), percentage body fat in top 40% (P). There were 1507, 3082, 3997, and 247 participants in O, W, F, and P phenotype, respectively.Table 1Characteristics of study sample in different obesity phenotypes.VariablesBMI \> 27 (O) (N = 1507)High WC (W) (N = 3082)Fatty liver (F) (N = 3997)High PBF (P) (N = 247)**Continuous Variables, mean (SD)**Age (years)43.7 (14.5)44.9 (13.4)48.7 (12.3)50.6 (13.4)Body Mass Index (kg/m^2^)30.1 (3.1)28.1 (4.0)25.8 (3.7)27.9 (3.7)Percentage body fat (%)33.7 (6.7)32.9 (6.5)29.9 (7.0)36.3 (5.0)Waist circumference (cm)93.5 (9.2)92.4 (8.3)87.6 (9.9)92.4 (10.2)Total cholesterol (mmol/L)4.9 (0.9)4.9 (0.9)4.9 (0.9)5.1 (0.9)Uric acid (umol/L)384.2 (90.4)359.9 (90.4)365.8 (89.2)366.9 (91.0)Creatinine (umol/L)49.4 (17.0)47.1 (17.6)49.4 (15.3)47.7 (17.6)AST (units/L)24.0 (13.5)23.1 (13.3)22.7 (12.1)24.0 (13.9)Albumin (g/L)44.7 (3.0)44.5 (3.0)44.8 (2.7)44.4 (2.7)hsCRP (nmol/L)31.4 (40.9)26.7 (41.9)24.8 (44.8)30.5 (39.1)**Category Variables, (%)**Gender (male)6971 (65.6)7179 (53.0)6665 (67.7)1973 (55.1)Proteinuria3047 (32.3)3608 (31.4)2659 (26.6)861 (26.9)Smoking1641 (38.5)2176 (31.4)3570 (33.0)1035 (29.0)Drinking2031 (55.2)2895 (48.3)4727 (49.4)1440 (44.7)

Association between obesity phenotypes and the presence of DM, HTN and MetS {#Sec4}
---------------------------------------------------------------------------

Tables [2](#Tab2){ref-type="table"}--[4](#Tab4){ref-type="table"} showed the associations between different combinations of obesity phenotypes and the presence of DM, HTN, and MetS. There were 15 combinations as following: O, W, F, P, O + W, O + F, O + P, W + F, W + P, P + F, O + W + F, O + W + P, O + F + P, W + F + P, and O + W + F + P.Table 2Association between various combinations of obesity phenotypes and the presence of DM.VariableModel^a^ 1 OR (95% CI)*P* ValueModel^a^ 2 OR (95% CI)*P* ValueModel^a^ 3 OR (95% CI)*P* ValueO (BMI \> 27 kg/m^2^)1.73 (0.23--13.01)0.5922.69 (0.35--20.51)0.3402.72 (0.36--20.83)0.334W (high waist circumference)1.41 (0.72--2.78)0.3151.44 (0.72--2.87)0.2991.42 (0.71--2.84)0.319F (fatty liver)3.81 (2.61--5.55)\<0.0012.88 (1.95--4.25)\<0.0012.85 (1.93--4.21)\<0.001P (percentage body fat in top 40%)3.38 (1.48--7.71)0.0041.92 (0.81--4.54)0.1381.93 (0.81--4.56)0.136O + W2.68 (0.94--7.65)0.0673.38 (1.15--9.91)0.0273.34 (1.14--9.80)0.028O + F2.22 (0.52--9.44)0.2802.08 (0.48--9.00)0.3272.11 (0.49--9.11)0.318O + P------------------W + F4.26 (2.78--6.53)\<0.0013.37 (2.17--5.24)\<0.0013.31 (2.13--5.15)\<0.001W + P3.83 (1.75--8.36)\<0.0012.36 (1.04--5.36)0.0402.32 (1.02--5.29)0.045P + F4.16 (2.22--7.78)\<0.0012.33 (1.20--4.51)0.0122.35 (1.21--4.57)0.011O + W + F5.24 (3.20--8.58)\<0.0014.61 (2.76--7.69)\<0.0014.43 (2.65--7.40)\<0.001O + W + P7.10 (3.52--14.31)\<0.0014.38 (2.08--9.20)\<0.0014.25 (2.02--8.94)\<0.001O + F + P11.43 (4.78--27.32)\<0.0018.31 (3.33--20.74)\<0.0018.07 (3.23--20.16)\<0.001W + F + P6.26 (3.97--9.86)\<0.0014.30 (2.66--6.96)\<0.0014.19 (2.59--6.78)\<0.001O + W + F + P9.02 (6.22--13.08)\<0.0016.63 (4.49--9.78)\<0.0016.55 (4.44--9.67)\<0.001^a^Adjusted covariates:Model 1 = age.Model 2 = Model 1 + proteinuria, serum total cholesterol, uric acid, creatinine, AST, albumin, hsCRP.Model 3 = Model 2 + history of smoking, drinking.Table 3Association between various combinations of obesity phenotypes and the presence of HTN.VariableModel^a^ 1 OR (95% CI)*P* ValueModel^a^ 2 OR (95% CI)*P* ValueModel^a^ 3 OR (95% CI)*P* ValueO (BMI \> 27 kg/m^2^)2.25 (1.01--5.05)0.0482.22 (0.98--5.04)0.0572.17 (0.96--4.93)0.064W (high waist circumference)1.34 (1.01--1.78)0.0401.44 (1.07--1.93)0.0151.44 (1.07--1.93)0.016F (fatty liver)1.66 (1.39--1.99)\<0.0011.15 (0.95--1.39)0.1441.16 (0.96--1.40)0.134P (percentage body fat in top 40%)2.30 (1.49--3.53)\<0.0011.55 (0.99--2.43)0.0561.54 (0.98--2.42)0.060O + W6.28 (4.05--9.74)\<0.0015.35 (3.38--8.46)\<0.0015.43 (3.43--8.60)\<0.001O + F3.73 (2.08--6.69)\<0.0012.48 (1.36--4.51)0.0032.47 (1.35--4.50)0.003O + P4.23 (1.00--17.78)0.0491.85 (0.41--8.42)0.4251.88 (0.41--8.58)0.414W + F2.85 (2.32--3.51)\<0.0012.25 (1.81--2.80)\<0.0012.27 (1.83--2.83)\<0.001W + P2.15 (1.39--3.32)\<0.0011.75 (1.11--2.76)0.0171.75 (1.11--2.76)0.017P + F2.59 (1.85--3.62)\<0.0011.53 (1.08--2.18)0.0181.52 (1.07--2.16)0.021O + W + F3.20 (2.46--4.16)\<0.0012.29 (1.74--3.01)\<0.0012.33 (1.77--3.07)\<0.001O + W + P3.31 (2.12--5.16)\<0.0012.40 (1.49--3.84)\<0.0012.44 (1.52--3.91)\<0.001O + F + P2.91 (1.47--5.78)0.0021.60 (0.79--3.24)0.1891.64 (0.81--3.33)0.167W + F + P3.43 (2.68--4.39)\<0.0012.47 (1.89--3.22)\<0.0012.49 (1.91--3.25)\<0.001O + W + F + P4.81 (3.98--5.80)\<0.0013.36 (2.74--4.12)\<0.0013.39 (2.77--4.16)\<0.001^a^Adjusted covariates:Model 1 = age.Model 2 = Model 1 + proteinuria, serum total cholesterol, uric acid, creatinine, AST, albumin, hsCRP.Model 3 = Model 2 + history of smoking, drinking.Table 4Association between various combinations of obesity phenotypes and the presence of MetS.VariableModel^a^ 1 OR (95% CI)*P* ValueModel^a^ 2 OR (95% CI)*P* ValueModel^a^ 3 OR (95% CI)*P* ValueO (BMI \> 27 kg/m^2^)2.69 (0.80--8.99)0.1082.48 (0.74--8.39)0.1432.53 (0.75--8.59)0.135W (high waist circumference)7.64 (5.57--10.48)\<0.0018.62 (6.22--11.95)\<0.0018.57 (6.18--11.88)\<0.001F (fatty liver)4.06 (3.11--5.32)\<0.0012.94 (2.23--3.87)\<0.0012.93 (2.22--3.86)\<0.001P (percentage body fat in top 40%)2.40 (1.21--4.76)0.0121.62 (0.81--3.26)0.1741.60 (0.80--3.22)0.188O + W34.69 (21.50--55.96)\<0.00128.16 (17.16--46.21)\<0.00127.77 (16.90--45.62)\<0.001O + F5.63 (2.66--11.94)\<0.0013.68 (1.72--7.91)\<0.0013.74 (1.74--8.03)\<0.001O + P8.97 (1.78--45.11)0.0083.84 (0.72--20.55)0.1163.60 (0.66--19.54)0.137W + F23.32 (17.48--30.48)\<0.00120.23 (15.34--26.68)\<0.00120.12 (15.25--26.54)\<0.001W + P13.78 (8.94--21.25)\<0.00112.50 (7.94--19.68)\<0.00112.36 (7.84--19.48)\<0.001P + F6.07 (3.99--9.24)\<0.0013.74 (2.43--5.77)\<0.0013.82 (2.47--5.89)\<0.001O + W + F47.19 (34.47--64.60)\<0.00136.73 (26.59--50.75)\<0.00136.25 (26.21--50.12)\<0.001O + W + P21.42 (13.55--33.86)\<0.00116.14 (9.95--26.17)\<0.00115.93 (9.80--25.88)\<0.001O + F + P17.93 (9.17--35.06)\<0.00110.52 (5.29--20.93)\<0.00110.65 (5.34--21.24)\<0.001W + F + P27.90 (20.70--37.60)\<0.00121.82 (15.93--29.88)\<0.00121.74 (15.87--29.78)\<0.001O + W + F + P51.34 (39.36--66.97)\<0.00138.03 (28.91--50.04)\<0.00138.26 (29.07--50.36)\<0.001^a^Adjusted covariates:Model 1 = age.Model 2 = Model 1 + proteinuria, serum total cholesterol, uric acid, creatinine, AST, albumin, hsCRP.Model 3 = Model 2 + history of smoking, drinking.

After fully adjusting for pertinent covariables, F was significantly associated with the presence of DM with odds ratios (ORs) of 2.85 (95% confidence interval (CI): 1.93--4.21). Other combinations of obesity phenotypes including O + W, W + F, W + P, P + F, O + W, O + W + P, O + F + P, W + F + P, and O + W + F + P also had significant association with the presence of DM (P \< 0.05). O + F + P had risk for the presence of DM with ORs of 8.07 (95% CI: 3.23--20.16). W was associated with the presence of HTN with ORs of 1.44 (95% CI: 1.07--1.93). O + W, O + F, W + F, W + P, P + F, O + W + F, O + W + P, W + F + P, and O + W + F + P also had significant relationship with the presence of HTN. O + W had significantly higher risk of the presence of HTN with ORs of 5.43 (95% CI: 3.43--8.60) than others. W and F were associated with the presence of MetS with ORs of 8.57 (95% CI: 6.18--11.88) and 2.93 (95% CI: 2.22--3.86). O + W, O + F, W + F, W + P, P + F, O + W + F, O + W + P, O + F + P, W + F + P, and O + W + F + P were significantly associated with the presence of MetS (P \< 0.05). O + W + F + P had higher risk for the presence of MetS than other combinations with odd ratios (ORs) of 38.26 (95% CI: 29.07--50.36).

Discussion {#Sec5}
==========

In our study, the primary finding was that different obesity phenotypes were significantly associated with the presence of DM and HTN. The presence of DM was more likely associated with F phenotype than others. Those with W phenotype had closer relationship with HTN. Furthermore, subjects with different combinations of obesity phenotypes had higher risks of cardiometabolic diseases than those with single obesity phenotype. The combination of obesity phenotypes seems to have increased risk of obese individuals on the process for developing adverse health outcomes.

The clinical usefulness of PBF on MetS risks was addressed based on a nationally representative sample^[@CR13]^. Cardiometabolic risk factors such as elevated blood pressure, dyslipidemia and hyperglycemia are substantially related to high PBF^[@CR10]^. In two large scale population-based surveys, the high PBF group had higher risks of cardiovascular diseases than low PBF group among normal-weight males^[@CR14]^. In an Italian study, subjects with high PBF had higher inflammatory biomarkers than control group, suggesting that high PBF might be an important indicator for MetS^[@CR15]^. Obese subjects with higher PBF have higher insulin resistance and pro-inflammatory cytokines than those with normal BMI^[@CR16]^. Insulin resistance plays an important role on the development of MetS caused by systemic inflammation with elevated circulating levels of CRP and TNF-α^[@CR17],[@CR18]^.

Adiposity was a common risk factor for DM and cardiometabolic diseases^[@CR19]^. Rodriguez demonstrated that body fat distribution was a strong influence on the development of glucose intolerance and DM^[@CR8]^. Previous studies had addressed the important roles for abdominal adiposity and specifically visceral fat accumulation on the development of prediabetes and DM^[@CR6],[@CR20],[@CR21]^. However, our findings revealed that general obesity was considered as a better phenotype for predicting the risks of DM for both gender groups. In a cross-sectional study of 4828 participants concerning the prediabetes and DM development, PBF may be more imperative than BMI and WC^[@CR22]^. Shea *et al*. indicated that participants in the highest tertile of PBF had high risks of developing cardiometabolic disease compared to those with low PBF^[@CR23]^. Excess body fat was associated with numerous comorbidities included HTN, insulin resistance, dyslipidemia and systemic inflammation. In patients with and without DM, the leptin-to-adiponectin ratio was a useful indicator to assess insulin resistance and atherosclerotic risks^[@CR24],[@CR25]^.

Non-alcoholic fatty liver disease (NAFLD) was highly prevalent in patients with DM^[@CR26]^. Numerous evidences had supported a strong relationship between NAFLD and diabetes risk that subjects would have approximately 5-fold risks of developing DM if they had NAFLD^[@CR27],[@CR28]^. The presence of NAFLD and prediabetes or DM was associated with significant hepatic insulin resistance compared with subjects matched for adiposity without a fatty liver^[@CR29]^. The plausible mechanism for NAFLD associated with prediabetes and DM in obesity was dysfunctional adipose tissue that promoted insulin resistance and pancreatic β-cell dysfunction^[@CR30],[@CR31]^. Lopez and his colleagues demonstrated that the presence of insulin resistance of adipose tissue deteriorated the progression of glucose metabolism by multiple pathways that include subclinical inflammation and lipotoxicity^[@CR29]^.

Increased WC, as defined as central obesity phenotypes in our study, was associated with elevated blood pressure^[@CR32]^. Central type body fat distribution was more closely associated with renal-related hypertension than peripheral type obesity^[@CR33]^. Previous studies had suggested that obesity-associated hypertension was characterized by an endothelial dysfunction^[@CR34]^. The relationship between obesity and endothelial dysfunction might be through several pathways such as insulin resistance, inflammation and free fatty acid metabolisms^[@CR35]^. Production of nitric oxide from oxidative stress might contribute to endothelial dysfunction in the pathophysiology of obesity. Hypoxia related adipose tissue inflammation secretes many reactive oxygen species and cytokines, leading to deterioration of nitric oxide signaling pathways in the endothelial cells^[@CR36]^. Elevated endothelin-1 activity also played an important role in obesity- associated endothelial dysfunction^[@CR37]^.

There were several potential limitations among our study. First, it was a cross-sectional design that casual inference was no assessible between obesity phenotypes and adverse outcomes. A longitudinal survey was suggested to be examined in further studies. Second, the study sample was obtained from health examinations in a single medical center. Limited ethnicity diversity in the participants might not reflect the association of obesity phenotypes and cardiometabolic diseases in racial difference. Third, the measurement for PBF in the health check-up was used by BIA, but not DEXA, a standard measurement for body composition with higher accuracy. Last, the diagnosis of fatty liver was determined by abdominal sonography, bias of image interpretation caused by physicians might occur. Despite the limitations mentioned above, our study had some advantages. A relatively large population-based sample included 20665 subjects was analyzed compared to others examined in small population. Besides, multivariable adjustment consisted with potential confounders and lifestyles such as smoking and alcoholic assumption was conducted in the statistical analysis.

Conclusion {#Sec6}
==========

In summary, our study emphasized the important characteristics of these four obesity phenotypes and various combinations for different clinical implications. Identifying the distinct obesity phenotypes associated with DM and HTN in general population has implications for the stratification of cardiometabolic risk. Better understanding the pathophysiological mechanisms underlined individual vulnerability and progression of cardiometabolic insults. Therefore, association between body fat distribution with metabolic alternation and prolonged follow-up research for predicting risks of incident cardiometabolic diseases were necessary.

Methods {#Sec7}
=======

Study design {#Sec8}
------------

The retrospective cross-sectional was performed from health examinations in Tri-Service General Hospital from 2010 to 2016. There were 69226 participants received comprehensive examinations enrolling in the health check-up during the period. According to the step-by-step orders of flow chart shown in Fig. [1](#Fig1){ref-type="fig"}, subjects with missing data such as biochemistry data, body composition exams, abdominal sonography was excluded. 48426 eligible participants were divided into non-obesity and various obesity phenotypes as following: O was defined as a BMI \> 27 kg/m^2^ according to the criteria of the Department of Health in Taiwan^[@CR4]^; W was defined as subjects with high WC (male: \> 90 cm; female \> 80 cm); F was defined as subjects with fatty liver diagnosed by abdominal sonography. P was categorized into subjects along with PBF in top 40% of the entire obesity population.Figure 1Flowchart of our study.

The protocol was approved by the Tri-Service General Hospital Institutional Review Board based on the Declaration of Helsinki. Written informed consent was obtained from participants prior to the study. During the entire study process, characteristics of participants correlated with individual identification were eliminated and remained anonymously.

Measurement of body composition {#Sec9}
-------------------------------

PBF was the indicator used in the study and was measured by BIA (InBody720, Biospace, Inc., Cerritos, CA, USA), an effective and validated method that was widely used for assessing body composition^[@CR38]^.

Definition of MetS {#Sec10}
------------------

MetS was diagnosed when having ≥3 of the following features: (1) large waist circumference (WC): a waistline that measures at least 80 centimeters for women and 90 centimeters for men; (2) high triglyceride levels (TG): higher than 150 mg/dL; (3) reduced high-density lipoprotein cholesterol (HDL-C) levels: less than 50 mg/dL in women and 40 mg/dL in men; (4) increased blood pressure (BP): 130/85 mmHg or higher; and (5) elevated fasting plasma glucose (FPG): 100 mg/dL or higher based on the Harmonized criteria for MetS in 2009 with the Asian cut-off for WC^[@CR39],[@CR40]^.

Definition of type 2 DM {#Sec11}
-----------------------

As reported by the American Diabetes Association criteria, subjects with one of the following components were diagnosed of T2DM: (1) fasting plasma glucose ≥126 mg/dL (2) hemoglobin A1c test ≥6.5% (3) random plasma glucose ≥200 mg/dL (4) past history of diabetes status, or use of antidiabetic agents^[@CR41]^.

Definition of HTN {#Sec12}
-----------------

Participants who had HTN was diagnosed by the guidelines of the Taiwan Society of Cardiology and the Taiwan Hypertension Society for the management of hypertension (1) blood pressure was higher than 140/90 mmHg (2) subjects were taking antihypertensive agents^[@CR42]^.

Covariates measurement {#Sec13}
----------------------

BMI was calculated by a formula that the weight of the subject in kilograms divided by the square of the height in meters (kg/m^2^). WC was measured at the mid-level between the iliac crest and the lower border of the 12^th^ rib. Biochemistry data was collected by drawing blood samples from subjects after fasting for at least 8 hours. Serum profiles included total cholesterol (TC), uric acid (UA), creatinine (Cr), aspartate aminotransferase (AST), albumin, and C-reactive protein (CRP) were analyzed by using standard methods.

Statistical analysis {#Sec14}
--------------------

Statistical estimations used in the study were performed by the Statistical Package for the Social Sciences, version18.0 (SPSS Inc., Chicago, IL, USA) for Windows. The differences among these obesity phenotypes in terms of demographic information and biochemistry data were examined by analysis of variance and chi-square test. A two-sided *p*-value of ≤ 0.05 was regarded as the threshold for statistical significance. Extend-model approach was performed in the study with multivariable adjustment for pertinent clinical variables. ORs of different obesity phenotype combinations for the presence of DM and HTN were performed by a multivariate logistic regression.
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